Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on: January 04,2024

Using mathematical modeling and dynamic biomarkers to characterize metastatic disease during adaptive therapy

byH. Lee Moffitt Cancer Center & Research InstituteMathematical model overview and design. A, Simulated treatment trajectory. During the seeding/growth phase, metastases are seeded and grown

Updated on:January 04,2024

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on: October 12,2023

Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia

September 5, 2023Kristi RosaThe National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma w

Updated on:October 12,2023

ATR inhibition using gartisertib in patient-derived glioblastoma cell lines

by Impact Journals LLCUpregulated genes and pathways enriched in glioblastoma cell lines treated with gartisertib combined with TMZ+RT. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28

Updated on: May 11,2024

ATR inhibition using gartisertib in patient-derived glioblastoma cell lines

by Impact Journals LLCUpregulated genes and pathways enriched in glioblastoma cell lines treated with gartisertib combined with TMZ+RT. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28

Updated on:May 11,2024

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on: December 21,2023

New epigenetic markers for prostate cancer discovered

byGarvan Institute of Medical ResearchHistopathological image of a high grade prostate cancer. Credit: Prof James KenchNew epigenetic biomarkers to predict more aggressive forms of prostate canc

Updated on:December 21,2023

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on: October 11,2023

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10, 2023Jonah FeldmanTreatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable sa

Updated on:October 11,2023

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on: December 19,2023

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on:December 19,2023

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on: October 24,2024

Study ties diabetes and obesity to increased risk of liver cancer relapse

byOsaka Metropolitan UniversityDiabetes mellitus and obesity are risks for late postoperative recurrence of hepatocellular carcinoma. Credit: Osaka Metropolitan UniversityHepatocellular carcinom

Updated on:October 24,2024

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of

Updated on: May 26,2024

Is cold water bad for you? What about drinking from the hose or tap? The facts behind five water myths

by Oliver A.H. Jones,The ConversationCredit: Unsplash/CC0 Public DomainWe know theimportance of staying hydrated, especially in hot weather. But even for something as simple as a drink of

Updated on:May 26,2024

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023